Rationale Functional interactions between limbic regions that process emotions and frontal networks that guide response functions provide a substrate for emotional cues to influence behavior. Stimulation of postsynaptic α 2 adrenoceptors enhances the function of prefrontal regions in these networks. However, the impact of this stimulation on the emotional biasing of behavior has not been established. Objectives This study tested the effect of the postsynaptic α 2 adrenoceptor agonist guanfacine on the emotional biasing of response execution and inhibition in prefrontal cortex. Methods Fifteen healthy young adults were scanned twice with functional magnetic resonance imaging while performing a face emotion go/no-go task following counterbalanced administration of single doses of oral guanfacine (1 mg) and placebo in a double-blind, cross-over design.
Introduction
Socially appropriate behavior requires the encoding of context-dependent emotional cues to guide decisions about which actions to perform and which actions to suppress (Haberman and Whitney 2007) . The facial expressions and body gestures that convey these emotional cues in social contexts have also been found to influence multiple domains of cognitive function (Phelps and LeDoux 2005) , including response selection, execution, and inhibition (Maxwell et al. 2005; Schulz et al. 2007 ). Thus, the positive affect (Otta et al. 1994 ) and approach behavior (Johansson and Ronnberg 1996) elicited by facial expressions of happiness resulted in faster responses that were more difficult to suppress (Hare et Electronic supplementary material The online version of this article (doi:10.1007/s00213-012-2893-8) contains supplementary material, which is available to authorized users. Schulz et al. 2007) , while expressionless (neutral) faces reduced the accuracy of responses to happy and sad faces Lewis et al. 2008) . Identifying the neural mechanisms that support the emotional biasing reflected in response functions has important implications for addressing the problems with impulsivity and emotion regulation that characterize a wide array of psychiatric disorders (Lewis et al. 2008; Murphy et al. 1999; Musser et al. 2011; Silbersweig et al. 2007; Walcott and Landau 2004) .
Functional interactions between limbic structures that process affective cues and prefrontal cortex regions that guide behavior provide a putative cortical entry point for emotion to bias response functions (Dolan 2007) . The amygdala is a core component of a limbic network for rapidly detecting and encoding the intensity and valence of emotionally salient stimuli (Dolan 2007; LeDoux 1998) and sends extensive projections to orbital aspects of inferior frontal gyrus (Petrides and Pandya 2002) . The inferior frontal gyrus pars orbitalis integrates this emotional information with contextual input from inferotemporal cortex to compute the behavioral significance of cue stimuli (Sakagami and Pan 2007) , with separate sets of neurons coding for cues that signal behavioral execution and inhibition (Sakagami et al. 2001) . In turn, dorsolateral prefrontal cortex (DLPFC) integrates the pars orbitalis output and visuomotor input from parietal association cortices to exert goal-directed control by biasing neural activity in task-related sensorimotor regions (Egner and Hirsch 2005; Miller and Cohen 2001) and releasing frontal operculum from inhibitory control (Stevens et al. 2007 (Stevens et al. , 2009 . Right frontal operculum is purportedly a neural effector for both goal-directed hand actions (Iacoboni and Wilson 2006) and the inhibition of such actions (Garavan et al. 2006; Xue et al. 2008 ) and has been shown to display both context-and valence-dependent variations in activation during response inhibition ).
Prefrontal cortex function is intricately modulated by ascending noradrenergic projections from the pontine nucleus locus coeruleus (Arnsten and Li 2005) . Noradrenaline released from these projections acts at postsynaptic α 2 adrenergic receptors to suppress spontaneous activity (Wang et al. 2011 ) and increase evoked firing of pyramidal neurons (Carr et al. 2007; Gamo et al. 2010) , thereby enhancing the response gain of prefrontal neuronal ensembles to taskrelevant inputs (Aston-Jones and Cohen 2005) . This increase in response gain has been shown to boost the cueevoked activation of DLPFC ) and may contribute to improvements in response inhibition and increases in frontal opercular activation produced by the noradrenaline reuptake-inhibitor atomoxetine (Chamberlain et al. 2006; . These α 2 adrenoceptor actions offer a mechanism to enhance the top-down control of the emotional biasing of response functions using α 2 adrenoceptor agonists already approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) (Sallee and Eaton 2010) .
This study tested the impact of postsynaptic α 2 adrenoceptor stimulation on the emotional biasing of response functions in healthy adults using event-related functional magnetic resonance imaging (fMRI) together with a pharmacological challenge with the α 2 adrenoceptor agonist guanfacine. The adults were scanned twice while performing a face emotion go/no-go task following single oral doses of guanfacine and placebo in a double-blind, counterbalanced design. It was predicted that guanfacine stimulation of postsynaptic α 2A adrenoceptors would be associated with activation gains in inferior frontal gyrus pars orbitalis, DLPFC, and frontal operculum, which reflect enhanced cognitive control to overcome the reported emotional biasing of response functions, and would result in improved accuracy of responses to sad faces and inhibition of responses to happy faces compared to placebo.
Methods

Participants
Fifteen right-handed adults (eight females) with a mean (±SEM) age of 25.7±1.2 years (range021-35 years) were recruited via university and medical center campus postings for the study. All participants provided written informed consent for participation after a complete description of the study was provided to them. Participants were compensated for their time. The study was approved by the Institutional Review Boards of Queens College and The Mount Sinai School of Medicine.
Subjects were screened for contraindications to study participation with physical and mental status exams, and ratings on the Beck Anxiety Inventory (BAI) (Beck et al. 1988 ), Beck Depression Inventory-II (BDI-II) (Steer et al. 1999) , and Conners Adult ADHD Rating Scale (CAARS) (Conners et al. 1999) . Full Scale IQ was estimated with the Matrix Reasoning and Vocabulary subtests of the Wechsler Abbreviated Scale of Intelligence (Wechsler 1999) . A total score≥15 on the BDI-II or the BAI, a T score 1 SD above the mean (i.e., >60) on the CAARS Total ADHD Symptoms index, and an estimated IQ<80 were exclusionary for the study. Mean BDI-II and BAI total scores were both 1.4±0.5, mean CAARS total ADHD symptoms T score was 42.9± 2.5, and mean estimated IQ was 113.7±9.6.
General experimental design
Participants completed fMRI scans on two separate days, with a mean of 7.0±2.5 days between scans. Blood pressure was measured and 1 mg oral guanfacine or placebo was administered 90 min prior to the scans in a counterbalanced, double-blind design. The 1-mg dose of guanfacine was chosen to minimize sedation in the scanner and for its primarily postsynaptic binding profile (Arnsten et al. 1988; Engberg and Eriksson 1991) . Participants completed a training session that tested simple face perception and presented the face emotion go/no-go task. Blood pressure was measured at the end of each scan session.
Face emotion go/no-go task
The face emotion go/no-go task has previously been described ). The task consisted of six 252-s blocks that each began and ended with a 30-s central fixation-cross. Each block contained 72 (75 %) go cues and 24 (25 %) no-go cues, yielding a total of 432 go cues and 144 no-go cues across the task. Participants had to respond rapidly with the right index finger to "go" cues and withhold responses to "no-go" cues. Stimuli were presented in the center of the screen for 500 ms with an interstimulus interval that was pseudorandomized from 1,250 to 1,750 ms (mean per block01,500 ms). Face stimuli consisted of gray-scaled happy, sad, and neutral facial expressions from 18 individuals (9 female, 9 male) from the MacBrain Face Stimulus Set (Tottenham et al. 2009 ; available at www.macbrain.org). The images were normalized for size and luminance, morphed to exclude hair, and cropped into a black square, which was presented against a black background. Alternating the valence of the face stimuli used as trial cues resulted in six blocks with the following trials: (1) happy go/sad no-go; (2) sad go/neutral no-go; (3) neutral go/happy no-go; (4) happy go/neutral no-go; (5) sad go/happy no-go; and (6) neutral go/sad no-go. Trial order was determined by counterbalancing across all conditions in the task (e.g., trial type, facial expression, face ethnicity, face gender, face) to ensure that each trial type followed every other trial type equally often. fMRI image acquisition All participants were scanned on the same 3.0 Tesla Siemens Allegra (Siemens, Erlangen, Germany) head-dedicated MRI scanner. Functional T2*-weighted images depicting the blood oxygenation level-dependent (BOLD) were obtained every 3 s (TR03) using gradient-echo echo-planar imaging. Each functional image comprised a brain volume of 42 axial slices with an in-plane resolution of 3.75×3.75 mm and a thickness of 2.5 mm with a gap of 0.825 mm. The matrix size was 64×64, and the field of view was 210 mm. The TR was a trade-off for whole-brain coverage with thinner slices that minimized distortions and increased sensitivity in regions of interest (e.g., inferior frontal gyrus pars orbitalis). The participants each completed six runs of 252 s on two separate days. A highresolution T2-weighted anatomical image was also acquired at the same 42 slice locations with a turbo spin-echo pulse sequence. All images were acquired with slices positioned parallel to the intercommisural line.
Behavioral analysis
Percent correct responses on go trials served as the measure of response execution, while percent correct inhibitions on no-go trials was the primary measure of response inhibition. Reaction time (RT) was also calculated for go trials. The signal detection variables d-prime (d′) and criterion (c) were computed to measure discriminability and response bias, respectively (Macmillan and Creelman 2005) . The variables d′ and c were calculated from the hit and false alarm rates and thus provided pooled measures of performance on both go and no-go trials. Higher d′ values indicate greater discriminability, while negative c values indicate a bias to respond (as opposed to a bias to inhibit), with larger negative values indicating greater bias (Stanislaw and Todorov 1999) .
The effects of guanfacine and emotion on performance were tested with repeated measures analyses of variance (ANOVA) with face emotion (happy vs. sad vs. neutral) and drug (guanfacine vs. placebo) as within-subject factors. Separate ANOVA with drug (guanfacine vs. placebo) and time (pre-scan vs. postscan) as within-subject factors were used to test the effect of guanfacine on blood pressure. Statistical significance was set at the 0.05 level for these analyses. All probabilities were based on two-tailed tests. Partial eta squared (η p 2 ) values were calculated to estimate the size of the guanfacine and emotion effects on behavioral performance.
fMRI analysis
Pre-processing and analyses of the fMRI data were conducted using SPM8 software (http://www.fil.ion.ucl.ac.uk/ spm/). Each participant's placebo and guanfacine time series were separately corrected for the staggered acquisition of slices during echo-planar imaging and realigned to the first volume in each time series to correct for inter-scan motion. Next, the placebo and guanfacine time series were coregistered to their respective T2-weighted anatomical images and then to each other. The time series were subsequently spatially normalized to the Montreal Neurological Institute template using normalization parameters estimated from the first T2-weighted image and were then resampled with a 2×2×2 mm voxel size. Finally, the time series were spatially smoothed with an 8-mm full width at halfmaximum isotropic Gaussian kernel.
Event-related analyses were conducted individually for each participant using a general linear model (GLM) to determine the relationship between the observed eventrelated BOLD signals and regressors that represented expected neural responses to trial events. Regressors were created by convolving a train of delta functions that represented the individual trial events with the default SPM basis function, which consisted of a synthetic hemodynamic response function (Friston et al. 1998) . Twelve regressors were entered into the GLM, representing the two trial types of interest (correct no-go event vs. correct go event)×three face emotions (happy vs. sad vs. neutral)×two drugs (guanfacine vs. placebo). Go and no-go errors and six motion parameters were entered as covariates of no interest in the GLM (Johnstone et al. 2006) . Contrasting the parameter estimates for each regressor versus baseline resulted in 12 contrast maps that each represented the specific BOLD response to a single interaction effect (e.g., happy no-go trials in the guanfacine condition).
The 12 contrast maps for each participant were entered into a second-level group analysis that used a factorial ANOVA model with trial type, face emotion, and drug as within-subjects factors. This statistical model enabled us to test all possible two-way and three-way interactions. The resultant voxel-wise statistical maps were thresholded for significance using a cluster-size algorithm that protects against false-positive results (Hayasaka et al. 2004 ). The height (intensity) threshold of each activated voxel was set at a p value of 0.005 and the extent (cluster) threshold was fixed at κ>100 contiguous voxels. A Monte Carlo simulation that accounted for image resolution and smoothing parameters established that a cluster extent of 100 contiguous resampled voxels (2 mm 3 ) corrected for multiple voxel comparisons at p< 0.01. The simulation is described in Slotnick and Schacter (2004) .
Results
Blood pressure
Guanfacine reduced blood pressure during the scan compared to placebo (see Supplementary Table 1) . Repeated measures ANOVA revealed a significant main effect of time [F (1, 15)0 8.43, p00.012] and drug×time interaction [F (1, 15) 05.67, p00.032] on pulse rate, and a significant drug×time interaction on systolic blood pressure [F (1, 15) 07.17, p00.018], but not diastolic blood pressure (p00.88). Reductions in systolic blood pressure over the scan session were only seen for guanfacine, while decreases in pulse rate were seen for both conditions, but were greater for guanfacine than placebo. There were no significant main effects of drug (all p>0.10).
Behavioral performance
Guanfacine moderated the effect of face emotion on the accuracy of response execution on the go/no-go task but had no effect on response inhibition ( . Post-hoc Bonferroni tests revealed that the accuracy of responses was lower, and consequently, perceptual sensitivity and response bias were reduced for sad faces only in the placebo condition (Fig. 1) . There was also a significant effect of face emotion on RT on go trials [ Table 1 ; F (2, 28)09.02, p00.001, η p 2 00.39]. There were no significant main effects of drug (all p>0.10).
fMRI responses
Face emotion influenced neural activation for response execution and inhibition in prefrontal cortex and other regions. The factorial ANOVA identified significant main effects of trial type in two independent brain networks that have been linked to response execution and inhibition (Table 2) . Primary motor, striatal, and cerebellar regions showed greater activation for correct go trials than correct no-go trials, while greater activation for no-go than go trials was seen in frontal, parietal, and temporal regions, including left DLPFC and right frontal operculum extending superiorly to DLPFC. The latter region completely overlapped a separate cluster of activation in right frontal operculum that demonstrated a significant main effect of face emotion (Fig. 2) . Post-hoc comparisons revealed that activation in this frontal opercular cluster was greater for sad faces than neutral faces, which in turn was greater than the deactivation for happy faces (Fig. 3a) . Further, significant trial type×face emotion interactions were seen in right inferior frontal gyrus pars orbitalis, left primary motor cortex, and several parietal regions (Table 2 ). Plotting the inferior frontal activation revealed that sad faces evoked activation for go trials versus deactivation for no-go trials, but happy and neutral faces evoked activation for no-go trials versus deactivation for go trials (Fig. 3b ). This pattern of activation was conserved across the motor and parietal clusters. Guanfacine moderated the effect of face emotion on neural activation for response execution and inhibition selectively in left DLPFC ( Table 2 ). The ANOVA identified a trial type×face emotion×drug interaction in a cluster that partially overlapped with the DLPFC region that showed an effect of trial type (Fig. 2) . Guanfacine reversed the valencedependent pattern of activation for go and no-go trials seen in this cluster following placebo. Thus, sad faces evoked activation for no-go trials in the placebo condition and for go trials in the guanfacine condition, whereas happy faces, and to a lesser extent neutral faces, elicited activation for go trials following placebo and for no-go trials following guanfacine (Fig. 3c) . In addition, significant main effects of drug and trial type×drug interactions were found in disparate regions that are not typically engaged for go/no-go tasks ( Table 2 ).
Discussion
The current results provide evidence that the α 2 adrenoceptor agonist guanfacine moderates left DLPFC activation associated with the emotional biasing of response execution in healthy adults. Left DLPFC is part of a wider frontoparietal network that is specialized to use emotional and contextual information to guide response execution and inhibition. Frontal opercular, inferior frontal, DLPFC, and parietal areas of this network all showed variations in activation as a function of face valence that were comparable to that seen in a previous study ). Guanfacine moderated the effect of face emotion on this activation selectively at the level of DLPFC, by reversing the valence-dependent pattern of task-related activation, which resulted in activation for response execution and deactivation for response inhibition cued by sad faces relative to happy and neutral faces. These guanfacine actions were associated with selective increases in the relatively low sensitivity and response bias for sad faces seen in the placebo condition, which principally reflected improvements in response execution. In contrast, neither face valence nor guanfacine had an effect on response inhibition. These results offer clues about the emotional biasing of motor functions and the manipulation of this bias by α 2 adrenoceptor stimulation.
The present behavioral findings provide clear evidence that emotional cues bias response execution processes on the go/no-go task. The negative values for the signal detection measure c in the current study indicate a bias to respond rather than inhibit for all three face emotions, with less response bias for sad than happy and neutral faces (Stanislaw and Todorov 1999) . The differences in response bias across the face emotions were mainly due to fewer correct responses to sad faces, which is partially consistent with our previous report of less accurate responses to both sad and happy faces ). Moreover, the enhanced response bias and perceptual sensitivity for sad faces following guanfacine reflected an increase in the percentage of correct responses to sad faces. However, unlike previous studies, our finding of faster responses to happy faces did not seem to reflect a broader emotional bias that interfered with the inhibition of responses to happy faces on no-go trials (i.e., fewer correct inhibitions) (Hare et al. 2005; Schulz et al. 2007) . Rather, both findings may reflect the inclusion of neutral faces as trial cues. Neutral expressions tend to be mistakenly evaluated as sad faces (Lee et al. 2008; Russell and Fehr 1987) , which may have been further compounded by the use of faces with closed mouths (Calvo and Nummenmaa 2008) . These difficulties with face discrimination could account for both the poorer accuracy for sad faces and the slower responses to neutral and sad faces than happy faces in this study. The selective effect of guanfacine on the emotional biasing of accuracy for sad faces confirms that these effects were task-specific rather than a general consequence of the medication.
The selective impact of guanfacine on the valence-and task-dependent activation of left DLPFC is consistent with the model of this region as the apex of a frontoparietal network for the context-dependent control of goal-directed behavior (Fuster 2002; Miller and Cohen 2001) . Left DLPFC receives limbic and inferotemporal input indirectly via inferior frontal gyrus pars orbitalis (Petrides and Pandya 2002) and represents this input as distinct patterns of neural F values and x, y, and z coordinates refer to the peak voxel of activation within each cluster. All regions were significant at p <0.005, extent threshold corrected for multiple voxel comparisons at p<0.01. There were no significant Emotion×Drug interaction effects BA Brodmann area, DLPFC dorsolateral prefrontal cortex, MNI Montreal Neurological Institute a no-go>go for sad but go>no-go for happy and neutral b no-go>go for placebo but go> no-go for guanfacine c (no-go > go for sad but go>no-go for happy and neutral) for placebo but (go>no-go for sad but no-go > go for happy and neutral) for guanfacine activation (Fuster 2002; Miller and Cohen 2001) . These context representations form the neural basis for DLPFC to exert top-down control over sensorimotor processors that directly support task performance (Sakagami and Pan 2007; Silton et al. 2010) , by amplifying responses to task-relevant signals (Egner and Hirsch 2005) , particularly in the presence of competing response options, such as for sad faces in the current study (Hester et al. 2004 ). The guanfacine reversal of the DLPFC function for response to sad faces, from deactivation to activation relative to responses cued by happy and neutral faces, may thus reflect increases in topdown control to overcome the difficulties with responding to sad faces.
The gain in DLPFC activation associated with improvement in response execution cued by sad faces is consistent with the well-described neural actions of guanfacine. Guanfacine stimulation of postsynaptic α 2 adrenoceptors suppresses an inward cation current (Wang et al. 2007) , which raises the excitability of pyramidal neurons (Carr et al. 2007 ) and strengthens local DLPFC recurrent networks that support top-down attention control (Wang et al. 2007 ). These α 2 adrenoceptor actions have been shown to increase neuronal firing in DLPFC for the preferred direction in a working memory task in monkeys (Avery et al. 2000; Gamo et al. 2010) . Similar mechanisms may have improved response execution for sad faces in the current study. The valence-and task-dependent activation of the inferior frontal gyrus pars orbitalis seen in the current study provides support for the model of this region as a cortical entry point through which emotional cues influence response functions (Sakagami and Pan 2007) . The pars orbitalis purportedly computes the behavioral significance of stimuli by integrating information about the target with affective input from amygdala (Petrides and Pandya 2002) and contextual input from inferotemporal cortex (Ungerleider et al. 1989) , and is unique among prefrontal areas in that it contains separate populations of neurons that fire selectively for sensory cues that signal behavioral execution and inhibition (Sakagami et al. 2001) . The interactive effect of face valence and trial type on pars orbitalis activation in the current study is consistent with the integration of emotional and contextual cues. The pars orbitalis may influence motor functions through projections to DLPFC (Miyachi et al. 2005 ) and dense connections with the frontal operculum (Petrides and Pandya 2002) .
The frontal operculum on the non-dominant side has been implicated in complex sensory guided motor acts (Iacoboni and Wilson 2006) . The current finding of greater frontal operculum activation for no-go relative to go trials is consistent with meta-analyses that have implicated the region as a neural effector for response inhibition (Garavan et al. 2006; Simmonds et al. 2008) . The overlapping region of operculum that independently displayed greater activation for sad faces than neutral and happy faces may thus have reflected differences in the difficulty of inhibiting responses to sad faces ). The lack of an interaction between face valence and trial type points to an exclusive role for frontal operculum in response inhibition. The fact that guanfacine did not influence activation in frontal operculum may explain the lack of effect of the α 2 adrenoceptor agonist on response inhibition in this study and others (e.g., Muller et al. 2005) . Gains in frontal opercular activation have previously been associated with improvements in response inhibition in healthy adults (Chamberlain et al 2009) .
Limitations
The attribution of the behavioral and neural changes in the current study to the biochemical effects of guanfacine is mitigated by the difficulties with measuring local drug actions in humans. Plasma measures of guanfacine and its metabolites that would have strengthened claims of causality were purposely not obtained to minimize participant risk and burden. However, the depressant effect that guanfacine had on blood pressure recordings in this study confirm that the medication, which was originally developed as an antihypertensive, had the desired biochemical effects, at least peripherally.
The absence of face valence effects in amygdala and other limbic regions in this study was unexpected given the previous reports of such activation using emotional go/ no-go tasks Goldstein et al. 2007; Hare et al. 2005) . This lack of amygdala activation may reflect the difficulty with successfully imaging this subcortical region (Merboldt et al. 2001 ) and/or the focus on prefrontal cortex in this study, and the use of an analytic approach that was optimized to detect effects in this large region of interest. The extent or cluster threshold (>100 voxels) that was needed to correct for the multiple voxel comparisons may have been too large to detect effects in the relatively small amygdala. It must also be noted that the relatively small sample size in this study may have limited the statistical power to detect more subtle effects of guanfacine, especially on the behavioral measures of response execution and inhibition.
Clinical implications
The current findings have potential implications for the α 2 adrenoceptor agonist treatment of psychiatric disorders characterized by problems with impulsivity and emotion regulation. The specific effect of guanfacine on the response bias for sad faces suggests an application for α 2 adrenoceptor agonists in the treatment of the mood-congruent biases that characterize major depression (Blaney 1986 ). However, α 2 adrenoceptor agonists have no reported antidepressant properties, and successful antidepressant treatment does not seem to involve alterations of adrenoceptor function (Charney et al. 1984; Price et al. 1986 ). The lack of antidepressant effects may in part reflect the selective action of guanfacine on executive functions mediated by DLPFC (Jakala et al. 1999) , rather than on the limbic affective mechanisms that have been implicated in both moodcongruent biases (Elliott et al. 2000 (Elliott et al. , 2002 and the pathophysiology of major depression (Elliott et al. 2011) .
The guanfacine modulation of DLPFC activation associated with emotional biasing of response execution may offer a possible mechanism to address the emotional reactivity and dysregulation that are common to ADHD (Musser et al. 2011; Walcott and Landau 2004) . Clinical experience and the few available studies suggest that these emotion regulation problems are not necessarily well served by the psychostimulant medications used to treat ADHD (Manos et al. 2011; Pelham et al. 1991) . The finding that guanfacine enhanced response-related DLPFC activation to increase the reduced bias and sensitivity for sad faces suggests that the medication may improve emotion regulation and reduce the extraneous influence of emotion on response functions in individuals with noradrenergic dysfunction. Suboptimal postsynaptic α 2A adrenoceptor regulation of DLPFC function has been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD) (Brennan and Arnsten 2008) and is a promising target for pharmacological treatments for the disorder ). Our results support further investigation of the use of guanfacine to treat affect-related regulatory problems in individuals with ADHD.
Conclusions
The present results demonstrate that the α 2 adrenoceptor agonist guanfacine moderates left DLPFC activation associated with the emotional biasing of response execution in healthy adults. Guanfacine inverted the trial-and valencedependent pattern of DLPFC activation, and thereby increased left DLPFC activation for responses to sad faces relative to happy and neutral faces. These guanfacine actions were associated with improvements in the poor accuracy of responses to sad faces relative to happy and neutral faces in the placebo condition, but had no effect on behavioral measures of response inhibition. The selective action of guanfacine on control networks centered in DLPFC may offer a possible mechanism to address the emotional reactivity and regulation deficits commonly seen in patients with ADHD.
